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Diagnostics
Guidelines for serological testing for syphilis
H Young
Although we may wish it were not so, syphilis,
like the poor, will always be with us—at least
for the foreseeable future. The levels of both
are determined to a large extent, by political
instability and socioeconomic deprivation.
Overall, the incidence of syphilis is low in
Western Europe (approximately 0.3 cases/
100 000 in England in 1998)1 although it has
reached epidemic proportions in the Russian
Federation where the levels in 1996 exceeded
900 cases/100 000 in men and women in the
20–29 year old age group.2 The need to main-
tain eVective strategies for syphilis control,
which must include diagnosis and manage-
ment, in areas of low prevalence such as the
United Kingdom, is reinforced by the recent
local outbreak of heterosexually acquired
syphilis in South West England3 as well as the
marked increase in homosexually acquired
infection in the Manchester area.4 A significant
proportion of the infected men in Manchester
were HIV positive so the overall community
health gain from rapid and eVective diagnosis
extends well beyond syphilis: ulcerative sexu-
ally transmitted infections promote HIV trans-
mission by augmenting HIV infectiousness and
HIV susceptibility via a variety of biological
mechanisms.5 The importance of the serologi-
cal diagnosis of syphilis has now been recog-
nised with the publication of the excellent
guidelines for serological testing for syphilis in
diagnostic microbiology laboratories by the
PHLS Syphilis Serology Working Group.6
These complement the recent national guide-
lines on the management of syphilis7 8 and
together they should improve the overall diag-
nosis and management of syphilis within the
United Kingdom and beyond.
Guidelines for serological diagnosis for
syphilis are long overdue. The last guidelines
which were produced by the World Health
Organization in 19829 recommended the use of
a cardiolipin antigen test such as the Venereal
Diseases Reference Laboratory (VDRL) or
rapid plasma reagin (RPR) test and the
Treponema pallidum haemagglutination assay
(TPHA) for screening for syphilis. The new
recommendations6 extend the WHO guide-
lines by suggesting that treponemal antigen
based enzyme immunoassays (EIAs) are an
appropriate alternative to the combined
VDRL/RPR and TPHA screen. EIA as a single
screening test was shown to give similar results
to the VDRL/RPR and TPHA combination
some years ago10 and is already used by many
laboratories, particularly those with large
workloads. Results of the UK National Exter-
nal Quality Assessment Scheme for Microbiol-
ogy syphilis serology distribution in April 2000
showed that 56% (130/232) of responding
laboratories within the United Kingdom used
an EIA (quoted with permission of the UK
NEQAS organiser). Advantages of EIA include
automated (or semiautomated) processing,
objective reading of results, and interfacing
with the laboratory computer system to allow
electronic report generation. The widespread
and growing use of automation and computeri-
sation in laboratories has led to the reorganisa-
tion and rationalisation of microbial serology to
meet the continuous demands for increased
cost eVectiveness in service delivery. Several
requests to the author for advice suggest that,
owing to rationalisation of services and devel-
opments in automation and computerisation,
there is a trend for syphilis testing to move from
bacteriology laboratories to dedicated micro-
bial serology laboratories that traditionally may
have dealt mainly with viral serology. These
changes make the guidelines particularly timely
as many laboratories may be taking on syphilis
testing for the first time. There is also a trend
for fewer laboratories to perform confirmatory
testing, preferring to forward specimens reac-
tive on screening to a specialised laboratory or
centre.
The guidelines outline the current serologi-
cal tests for syphilis and highlight the diVer-
ences in screening practice between the United
Kingdom and the United States. They contain
an excellent algorithm for “Treponemal anti-
body screening and confirmatory testing”
which is based on the key recommendations of
the group. The guidelines recognise that there
are a number of commercial tests of any given
format and that these can vary in performance
characteristics. Decisions on which test a labo-
ratory uses will be based on many factors
including cost, ease of use, suitability for auto-
mation, compatibility with the format of other
tests already in use in the laboratory, as well as
performance characteristics. Sadly, the changes
described above inevitably decrease the weight-
ing of performance characteristics in test selec-
tion. There is an enormous choice of test
reagents, manufactured and/or supplied by dif-
ferent companies. For example, of the UK
laboratories participating in the NEQAS
scheme there were 19 diVerent cardiolipin
tests, 13 TPHA/TPPA tests, nine EIAs, and
seven FTA-abs in use (quoted with permission
of the UK NEQAS organiser). It is important
that laboratories do not change reagents
frequently in order that they and their users
such as genitourinary medicine physicians
become fully conversant with the performance
characteristics of the particular tests used.
Published performance criteria following strin-
gent evaluation in independent centres are
available for very few of the numerous tests
(and their modifications) produced by diVerent
manufacturers. For example, there is a paucity
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of performance data for the various TPHA kits,
supplied by 12 diVerent companies, used in the
United Kingdom. There are also few evalua-
tions of the Treponema pallidum particle agglu-
tination assay (TPPA), which uses gelatin par-
ticles as a carrier rather than erythrocytes, and
has replaced the TPHA in many laboratories.
An early developmental report11 found that the
microcapsule agglutination method was supe-
rior to the THPA in detecting cases of primary
syphilis. More recently, Pope and colleagues in
the United States12 reported that the TPPA was
an appropriate substitute for the TPHA.
Another recent report found that the TPPA
was significantly more sensitive than the FTA-
abs and marginally more sensitive than the
TPHA,13 which makes the TPPA very suitable
as a confirmatory test.
The starting point for the algorithm is the
result of screening (either VDRL/RPR and
TPHA or EIA alone). Screening with a
non-treponemal test alone is not recom-
mended because of the potential for false nega-
tive results as a result of the prozone
phenomenon.14 A negative screening result is
reported as “Treponemal antibody NOT de-
tected but advise repeat if at risk of recent
infection.” The importance of repeat testing is
well founded because approximately 15% of
patients with primary syphilis will be seroneg-
ative at initial presentation.15 A reactive screen-
ing result should be confirmed with a trepone-
mal antigen test diVerent from that used in
screening (for example, TPHA if EIA is used
for screening) and a quantitative non-
treponemal test (VDRL/RPR). The various
scenarios which are then dealt with in detail
include: (a) confirmatory and non-treponemal
tests reactive; (b) confirmatory test reactive but
non-treponemal test negative; and (c) con-
firmatory test negative with a negative or reac-
tive non-treponemal test. Group (a) is the
group most likely to include untreated syphilis
(or other treponemal disease) at any stage and
it is suggested that an EIA for specific
antitreponemal IgM should be considered on
the basis of non-treponemal test titre and clini-
cal details. Positive IgM reactions are consid-
ered to be consistent with recent/active
treponemal infection: the commercially avail-
able Captia Syphilis-M EIA has a sensitivity of
93% in primary infection, 85% in secondary
infection, and 64% in early latent infection.16
However, it is noted that in the absence of a
history of adequate treatment, a negative result
does not exclude the need for treatment.
Irrespective of the IgM result VDRL titres
greater than 16 are rarely found in adequately
treated infections.17 Sera in group (b) are most
likely to be from treated patients or those with
untreated late latent infection. Occasionally,
however, sera from patients with primary
infection may give this pattern: I am aware of
two recent cases of primary syphilis where the
VDRL test was negative yet the screening EIA
was positive. Although the algorithm does not
include IgM testing of this group, IgM testing
should be undertaken in all cases of suspected
primary infection irrespective of the initial
screening results. In the absence of a history of
adequate treatment, a negative VDRL result,
like a negative IgM, does not exclude the need
for treatment: in one study16 all 33 patients with
untreated late latent syphilis gave a negative
Captia Syphilis-M EIA result. Group (c) is the
only group where additional confirmatory test-
ing is recommended. Where the first line con-
firmatory treponemal antigen test is negative
and the additional confirmatory treponemal
antigen test(s) and VDRL are negative then the
specimen can be reported as a false positive
screening test. If at least one additional
confirmatory test is reactive then this signifies a
low level of treponemal antibodies, which
could be the result of a treated or longstanding
infection or to an early primary infection. IgM
EIA testing will diVerentiate between these
possibilities. If the only reactive screening test
were the VDRL/RPR, and primary syphilis was
not suspected, the negative result in the
treponemal confirmatory test normally used
would seem suYcient to denote a biological
false positive reaction (if quantitative VDRL/
RPR positive) or a false positive VDRL/RPR
screening test (if quantitative VDRL/RPR
negative). Again, an IgM EIA test should be
performed when primary syphilis is suspected.
In all categories of treponemal infection a
repeat specimen is advised to confirm the find-
ings; this will normally be a week or so after the
initial specimen. It is also recommended that
all reactive specimens should be referred to one
of the PHLS syphilis specialist laboratories
listed at the end of the guidelines for reference
testing and to allow collection of surveillance
data.
While the detection of early infectious syphi-
lis is the priority of any syphilis testing
programme it must also be recognised that in
the United Kingdom most newly diagnosed
cases are late stage infection.1 The screening
schedules proposed in the guidelines take
account of this and achieve high sensitivity in
all stages of infection. However, depending on
the particular tests used and the quality of the
clinical/laboratory liaison there may be a failure
to detect a small proportion of untreated
primary infections at one end of the spectrum
and markers of long standing treated trepone-
mal infection at the other. The extent of these
failures will vary slightly and depend on the
particular tests used. By the time that signs and
symptoms of primary syphilis are present most
patients have detectable IgG and IgM18 but
before this there is a short window around 2–4
weeks post-infection when only IgM is detect-
able. Provided that the specificity of EIAs that
detect both IgM and IgG is as good as those
that detect only IgG, and the sensitivity in late
stage infection is also as good, it would be an
advantage to use the former type of EIA even
although primary syphilis is rare. Specificity is
important in terms of the cost and workload
involved in confirmatory testing and referral: a
0.5% decrease in specificity of a test used in a
laboratory screening 20 000 specimens per
year means an extra 100 referrals for confirma-
tion at a cost of around £1500 to £3000.
Even when highly specific screening tests are
used confirmatory testing is essential because
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of the low prevalence of syphilis. For example,
treponemal EIAs generally give a specificity on
screening of around 99.5%. However, if the
prevalence of syphilis in the test population is
0.5% (it will be lower in populations such as
antenatal patients) then the predictive value of
a positive screening test result is only 50%.
Applying a confirmatory test with the same
specificity to the sera reactive on screening
(prevalence of syphilis now 50% in this
population) will give a positive predictive value
of 99%. The guideline recommendation that
specimens that are reactive on screening
require confirmatory testing with a diVerent
treponemal test, of equal sensitivity, from that
used for screening and, ideally, greater specifi-
city highlights the shortcomings of the FTA-
abs, previously considered the “gold standard”
confirmatory test. Indeed the FTA-abs is not
recommended as the first line confirmatory
test. The specificity of the FTA-abs is poorer
than that of the other treponemal antigen
screening tests17 19 while certain newer EIAs are
significantly more sensitive than the
FTA-abs13 20 in detecting markers of past infec-
tion which means that the FTA-abs will fail to
confirm a small number of genuinely reactive
EIAs. The TPHA/TPPA is comparable with
the newer EIAs which means that the most
accurate confirmation of treponemal antibod-
ies will result from using the TPHA/TPPA to
confirm a reactive EIA or an EIA to confirm a
reactive TPHA/TPPA: the practicalities of
laboratory testing mean that the former
scenario is more likely. Although the FTA-abs
may have slightly greater sensitivity in early
primary infection a positive FTA-abs result
alone has poor specificity and in one study
more than 90% of such reactions were the
result of conditions other than syphilis.21 The
use of an anti-treponemal IgM to supplement
standard screening and confirmatory proce-
dures is a better approach to maximising the
detection of early primary infection than
relying on the FTA-abs. Other limitations of
the FTA-abs in initial confirmation include the
finding that false reactivity in the FTA-abs was
significantly associated with false reactive EIA
results22; and the subjective interpretation of
the test that may lead to bias when other test
results are known.23
These guidelines will not only be of immedi-
ate benefit to laboratories involved in syphilis
serology they will also act as an impetus to
review the provision of syphilis serology
services throughout the United Kingdom.
Review could lead to improvements in reliabil-
ity and cost eVectiveness of laboratory testing
via increased standardisation of screening tests
with clearly identified policies for referral of
confirmatory tests to appropriately resourced
regional or supraregional specialist/reference
centres. Such changes would also have enor-
mous benefit for the prompt surveillance of
infectious syphilis. Further guidelines dealing
with specific areas of syphilis serology such as
congenital infection, neurosyphilis and co-
existing HIV are promised.6 Guidance on
direct detection of Treponema pallidum in geni-
tal ulcers would also be welcome.
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